GLP-1 Weight Loss Timeline: Month-by-Month Results
Based on real clinical trial data from STEP and SURMOUNT trials. See what to expect on semaglutide and tirzepatide week by week.
Last updated March 2026 · Read our methodology
How Fast Do GLP-1 Medications Work?
GLP-1 receptor agonists work remarkably fast compared to traditional weight loss approaches. Most patients experience appetite suppression within days, measurable weight loss within weeks, and significant body composition changes within months. To understand why GLP-1 medications work so effectively, it helps to know they target multiple pathways in your brain and metabolism.
The clinical evidence comes from rigorous FDA-approval trials: the STEP 1-4 trials for semaglutide (Ozempic, Wegovy) and the SURMOUNT trials for tirzepatide (Mounjaro, Zepbound). These trials tracked thousands of patients over 68+ weeks and documented weight loss progression at each time point.
Month-by-Month Weight Loss Breakdown
Appetite suppression begins within days to 1 week. Gastrointestinal side effects peak and often improve by week 3-4. Sleep may improve despite appetite changes. Energy levels vary — some feel better, others experience fatigue initially.
By month 2, most patients have adapted to side effects. Weekly weight loss becomes more consistent (0.5-2 lbs per week typical). Side effects have usually resolved or become manageable. Patients often report improved food choices without conscious restriction.
Months 4-6 represent the steepest weight loss period. Weight loss continues at 1-2 lbs per week. Body composition changes become visually apparent. Clothes fit differently; many need to downsize.
By month 7, many patients experience weight loss plateau — a normal physiological response. Weekly weight loss slows to 0.3-0.8 lbs per week. Appetite suppression may weaken slightly. Portion control becomes more important. For guidance on pushing past this phase, explore strategies specific to mature adults or women navigating hormonal factors that influence plateaus.
After 12 months, weight loss typically plateaus. The medication's primary benefit shifts from active loss to prevention of regain. Continued medication is necessary to maintain results.
Semaglutide vs. Tirzepatide: Clinical Results Comparison
Both medications are GLP-1 receptor agonists, but tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP receptor agonist, which may explain superior weight loss results in head-to-head trials.
| Metric | Semaglutide (STEP Trials) | Tirzepatide (SURMOUNT Trials) |
|---|---|---|
| Week 12 Loss | 3-5% (0.4 mg dose) | 4-6% (2.4 mg dose) |
| Month 6 Loss | 10-12% | 12-15% |
| Week 68 (16 months) Loss | 15-17% (2.4 mg dose) | 20-21% (15 mg dose) |
| Maximum Dose | 2.4 mg weekly | 15 mg weekly |
| Titration Period | 16 weeks (0.25 mg increments) | 16 weeks (2.5 mg increments) |
| Side Effect Profile | Gastrointestinal (common but mild) | Gastrointestinal (slightly higher incidence) |
Note: These are average results. Individual outcomes vary significantly. Data from FDA-published clinical trial results and peer-reviewed literature.
The choice between semaglutide and tirzepatide can meaningfully affect your timeline. While semaglutide delivers solid, consistent results, tirzepatide's dual-mechanism approach often accelerates the months 2-6 period, which is why many patients and providers now prefer it for faster initial momentum.
Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.